Insider Transactions in Q1 2024 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 16
2024
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,632
-2.79%
|
$107,712
$66.81 P/Share
|
|
Jan 16
2024
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,963
+22.46%
|
-
|
|
Jan 16
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,235
-2.2%
|
$147,510
$66.81 P/Share
|
|
Jan 16
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,748
+18.97%
|
-
|
|
Jan 16
2024
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,235
-2.23%
|
$147,510
$66.81 P/Share
|
|
Jan 16
2024
|
Adam J. Townsend Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,748
+19.17%
|
-
|
|
Jan 16
2024
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
4,240
-3.74%
|
$279,840
$66.81 P/Share
|
|
Jan 16
2024
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
23,748
+17.3%
|
-
|
|
Jan 16
2024
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,851
-2.3%
|
$518,166
$66.81 P/Share
|
|
Jan 16
2024
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
72,094
+17.42%
|
-
|
|
Jan 16
2024
|
Caroline Baumal Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,445
+30.36%
|
-
|
|
Jan 16
2024
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
438
-0.6%
|
$28,908
$66.81 P/Share
|
|
Jan 16
2024
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,508
+21.07%
|
-
|
|
Jan 04
2024
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,751
-7.71%
|
$165,060
$60.05 P/Share
|
|
Jan 01
2024
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+22.61%
|
-
|
|
Jan 01
2024
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+22.61%
|
-
|
|
Jan 01
2024
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+16.89%
|
-
|
|
Jan 01
2024
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+0.89%
|
-
|
|
Jan 01
2024
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,341
+2.47%
|
-
|